TVGN TEVOGEN BIO HOLDINGS INC

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

WARREN, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that, following the Company’s recent press release highlighting the Direct Registration System (DRS) as a secure method of share ownership, it has received a number of inquiries from shareholders seeking additional information on how to transfer their shares to a DRS account.

In response, Tevogen will provide step-by-step guidance early next week to help interested shareholders register their shares directly with the Company’s transfer agent, Continental Stock Transfer & Trust.

The Company also notes that several of its largest shareholders, both internal and external, have elected to hold their shares via DRS, underscoring their confidence in this method of direct ownership.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701



EN
02/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TEVOGEN BIO HOLDINGS INC

 PRESS RELEASE

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to ...

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievement of specified financial milestones to be determined at a future date, which could include revenue and earnings targets. Any consideration of a special dividend would be subject to the Company’s future financial per...

 PRESS RELEASE

Tevogen to Align Long-Term Stock-Based Incentive Program With Company ...

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue WARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that the current time- and individual performance-based long-term stock incentive program will be modified to align awards with defined company milestones including revenue. The updated program will be applicable to all employees, officers, directors and consultants who are eligible to participate in the Company’s long term incentives plan. Tevogen Founder and CEO, Dr. Ry...

 PRESS RELEASE

Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell ...

Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025 Jan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare Conference WARREN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today reported significant scientific and operational milestones achieved in 2025 within its biotechnology operations, reflecting Tevogen’s continued execution toward a scalable, established, multi-program cell therapy development organization. In 2025, Tevogen advanced its proprietary ExacTcell™ platform, expa...

 PRESS RELEASE

Tevogen CEO Donates Shares to Support Education for Underprivileged Ch...

Tevogen CEO Donates Shares to Support Education for Underprivileged Children WARREN, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that its Founder and CEO, Dr. Ryan Saadi has made a charitable contribution of 230,000 shares of Tevogen common stock to SRLC USA, a United Nations-recognized 501(c)(3) nonprofit organization dedicated to serving underserved communities. “Education is one of the most powerful long-term investments we can make in building healthier, more equitable societies,” said Dr. Saadi. “I’m pleased to su...

 PRESS RELEASE

Tevogen CEO Donates Personal Shares to Support Local Fire Department

Tevogen CEO Donates Personal Shares to Support Local Fire Department WARREN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 50,000 shares of his personal holdings of Tevogen common stock to the Mt. Bethel Fire Company, supporting the organization’s mission to protect the Warren Township community. The donations reflect Dr. Saadi’s continued commitment to supporting first responders and the Warren Township community. “On behalf of the Mt. Bethel Fire Company, we’re since...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch